000			a
999			_c15817 _d15817
003			OSt
005			20211229132537.0
008			211229b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_915202 _a Wu, Gang
245			_aTherapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy on advanced non-squamous non-small cell lung cancer and influencing factors
250			_aVol.83(1), Jan-Feb
260			_aMumbai _bIndian Journal of Pharmaceutical Science _c2021
300			_a120-126p.
520			_aTo explore the therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy on advanced non-squamous non-small cell lung cancer and its in fluencing factors is the main objective. A total of 87 patients with advanced non-squamous non-small cell lung cancer treated in our hospital from October 2016 to May 2018 were enrolled and allocated into control group and observation group according to their disease conditions and willingness. Paclitaxel and cisplatin chemotherapy regimen was employed for control group, based on which pembrolizumab was used for observation group. Cellular immunity indices, cytokine indices, short-term efficacy, adverse reactions, and long-term prognosis were compared, and the factors affecting short-term ef ficacy and long-term prognosis were analyzed. After treatment, observation group exhibited increased cluster of differentiation 3+ T lymphocytes, cluster of differentiation 4+ T lymphocytes, and cluster of differentiation 4 +/cluster of differentiation 8+ ratio and decreased cluster of differentiation 8 + T lymphocytes compared with control group (p<0.05). After treatment, the levels of interleukin-6 and tumor necrosis factor-alpha in observation group were lower than those in control group (p<0.05). The short-term ef ficacy and long-term prognosis in observation group were better than those in control group (p<0.05), but statistically no signi ficant difference in the incidence rate of adverse reactions was found between the two groups (p>0.05). Decreased cluster of differentiation 4 +/cluster of differentiation 8+ ratio increased tumor necrosis factor-alpha level and chemotherapy were risk factors for the poor short-term efficacy and long-term prognosis in patients with advanced non-squamous non-small cell lung cancer (p<0.05), and clinical stage IV was a risk factor for the unfavorable long-term prognosis as well (p<0.05). Pembrolizumab combined with paclitaxel and cisplatin chemotherapy regimen can relieve the cellular immune suppression and alleviate inflammatory responses to improve the short-term efficacy and long-term prognosis, without raising the incidence rate of severe adverse reactions in the treatment of advanced non-squamous non-small cell lung cancer
650		0	_94639 _aPHARMACEUTICS
773	0		_tIndian journal of pharmaceutical sciences _dNew Delhi
856			_uhttps://www.ijpsonline.com/articles/therapeutic-effects-of-pembrolizumab-combined-with-paclitaxel-and-cisplatin-chemotherapy-on-advanced-nonsquamous-nonsmal.pdf _yClick here
942			_2ddc _cAR